Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
204 stopped studies mapped to Malignant Neck Neoplasm and descendants · 91% state a reason
Over the 204 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803… | Phase 1 / Phase 2 | terminated | Apr 25, 2017 | NantCell, Inc. | The study was terminated before any dose escalation occurred in order to pursue other studies… | Other (stated, no rule matched) |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | Phase 2 | withdrawn | Feb 6, 2018 | University of Chicago | unable to accrue | Enrollment / accrual |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy… | Phase 2 | withdrawn | Oct 16, 2023 | ECOG-ACRIN Cancer Research Group | A phase III trial of the investigational agent failed to pass futility boundaries at interim… | Efficacy / futility |
| NCT05328076 | Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography(ANGIO_PARA) | — | terminated | Apr 14, 2022 | IRCCS San Raffaele | We encountered problems in finding the necessary resources in the Institute | Other (stated, no rule matched) |
| NCT04161391 | Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors… | Phase 1 / Phase 2 | terminated | Nov 13, 2019 | Turning Point Therapeutics, Inc. | Adverse change in the risk/benefit. | Safety / toxicity |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | N/A | withdrawn | Jul 22, 2022 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA… | Phase 2 | terminated | Jul 26, 2018 | University of Arizona | Novartis has chosen to withdraw support for this trial | Other (stated, no rule matched) |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid… | Phase 2 | withdrawn | Feb 1, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT04739566 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive…(ANAPLAST-NEO) | Phase 2 | withdrawn | Feb 4, 2021 | Saint Petersburg State University, Russia | Lack of funding | Funding |
| NCT05472506 | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant… | Phase 1 | withdrawn | Jul 25, 2022 | Ikena Oncology | Sponsor Decision | Sponsor / business decision |
| NCT06189482 | Intermittent Oral-esophageal Tube Feeding in Delayed Dysphagia After Radiotherapy for…(NPC) | N/A | terminated | Jan 3, 2024 | Zeng Changhao | ethical issues | Other (stated, no rule matched) |
| NCT04140513 | Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced… | N/A | withdrawn | Oct 28, 2019 | Ohio State University Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT06248840 | Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for… | N/A | terminated | Feb 8, 2024 | Zeng Changhao | ethical issues | Other (stated, no rule matched) |
| NCT04327999 | Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System | Phase 2 | terminated | Mar 31, 2020 | Vanderbilt-Ingram Cancer Center | Funding ended | Funding |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated…(AcceleRET-MTC) | Phase 3 | withdrawn | Feb 18, 2021 | Hoffmann-La Roche | Due to several logistical challenges during start-up which could not be overcome study was… | Other (stated, no rule matched) |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122…(PANTHEoN) | Phase 1 | withdrawn | May 19, 2021 | Jennifer Choe | Funding | Funding |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before… | Phase 1 / Phase 2 | terminated | Aug 7, 2018 | Jonsson Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT05535023 | Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous… | Phase 2 | withdrawn | Sep 10, 2022 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive… | Phase 1 / Phase 2 | terminated | Sep 24, 2018 | Cullinan Therapeutics Inc. | Lack of efficacy | Efficacy / futility |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in…(ALpha-T) | Phase 2 | terminated | Nov 25, 2020 | Hoffmann-La Roche | The data from this study is no longer needed. | Other (stated, no rule matched) |
| NCT03555721 | CytID Analysis of Oral Lesions | — | terminated | Jun 13, 2018 | The University of Texas Health Science Center, Houston | low subject recruitment | Enrollment / accrual |
| NCT02698111 | Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | terminated | Mar 3, 2016 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT03544099 | Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr… | Phase 2 | terminated | Jun 1, 2018 | National Health Research Institutes, Taiwan | Difficult to recruit Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA | Enrollment / accrual |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With… | Phase 1 | withdrawn | Apr 11, 2011 | Fox Chase Cancer Center | Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients. | Enrollment / accrual |
| NCT02582008 | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With… | Early Phase 1 | terminated | Oct 21, 2015 | Wake Forest University Health Sciences | Slow accrual | Enrollment / accrual |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer… | Phase 2 | terminated | Sep 28, 2016 | National Cancer Institute (NCI) | Low accrual combined with expiration of study drug | Enrollment / accrual |
| NCT04868045 | Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid… | Phase 1 | withdrawn | Apr 30, 2021 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT05512767 | A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage… | N/A | withdrawn | Aug 23, 2022 | Mayo Clinic | PI retired and study not moving forward | Other (stated, no rule matched) |
| NCT03258008 | Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable… | Phase 2 | terminated | Aug 22, 2017 | M.D. Anderson Cancer Center | Closed the trial for infeasibility due to slow accrual | Enrollment / accrual |
| NCT05061940 | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status… | — | terminated | Sep 30, 2021 | Repertoire Immune Medicines | Development program terminated | Other (stated, no rule matched) |
| NCT03506048 | Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive… | Phase 2 | terminated | Apr 23, 2018 | Emory University | Study has been abandoned for lack of accrual | Enrollment / accrual |
| NCT01891695 | OPSCC N0 Nodal Control With Reduced IMRT | N/A | terminated | Jul 3, 2013 | Paul W. Read, MD | Study had very specific inclusion/exclusion criteria and difficult to recruit | Enrollment / accrual |
| NCT02408887 | Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in… | Phase 2 | terminated | Apr 6, 2015 | National Cancer Institute (NCI) | Slow/Insufficient accrual | Enrollment / accrual |
| NCT02363647 | Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic… | N/A | terminated | Feb 16, 2015 | Icahn School of Medicine at Mount Sinai | No Current Funding | Funding |
| NCT04831450 | Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2 | withdrawn | Apr 5, 2021 | University of Miami | Investigator Decision | Investigator |
| NCT04001413 | Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | Phase 2 | withdrawn | Jun 28, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sponsor withdrew funding | Funding |
| NCT03065218 | 99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid… | Phase 4 | terminated | Feb 27, 2017 | Medstar Health Research Institute | Insufficient recruitment | Enrollment / accrual |
| NCT03713021 | TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers | N/A | terminated | Oct 19, 2018 | Washington University School of Medicine | Equipment unavailable | Other (stated, no rule matched) |
| NCT00373711 | Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent… | — | withdrawn | Sep 8, 2006 | Stanford University | Abandoned | Other (stated, no rule matched) |
| NCT04224792 | Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors | N/A | withdrawn | Jan 13, 2020 | Mayo Clinic | Due to pandemic, unable to see patients | COVID-19 / pandemic |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | Phase 1 | terminated | Dec 11, 2015 | MacroGenics | Business decision (not for safety reasons) | Safety / toxicity |
| NCT02289807 | Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated… | N/A | withdrawn | Nov 13, 2014 | Sun Yat-sen University | not stated | Not stated |
| NCT03139747 | UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients… | Phase 2 | suspended | May 4, 2017 | Thomas Jefferson University | lack of accrual reevaluating feasibility | Enrollment / accrual |
| NCT03838692 | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Phase 2 | withdrawn | Feb 12, 2019 | Antonio Fojo | Closed by sponsor | Other (stated, no rule matched) |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid… | Phase 1 / Phase 2 | terminated | Apr 27, 2017 | Dana-Farber Cancer Institute | Study closed due to slow accrual and lack of efficacy. | Efficacy / futility |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | Phase 2 | terminated | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Lack of efficacy | Efficacy / futility |
| NCT03463889 | Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid… | Phase 2 | terminated | Mar 13, 2018 | University of California, San Francisco | Funding | Funding |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2… | Phase 2 | withdrawn | Jan 4, 2018 | The University of Hong Kong | Sponsor withdrew funding for Nivolumab | Funding |
| NCT02177838 | Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck… | N/A | terminated | Jun 30, 2014 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT01707056 | The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid… | N/A | withdrawn | Oct 15, 2012 | Medstar Health Research Institute | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Aug 6, 2024source: clinicaltrials